Desjardins, A., Peters, K. B., Vlahovic, G., Randazzo, D., Boulton, S., Lipp, E., … Friedman, H. (n.d.). Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. (Vol. 33, pp. 112s-112s). Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, McCormick Place, Chicago, IL.

Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Eric Lipp, Woody Massey, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.,” 33:112s-112s, n.d.

Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Lipp E, et al. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. In p. 112s-112s.

Desjardins, Annick, et al. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. Vol. 33, no. 15s, Part I of II, pp. 112s-112s.

Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Lipp E, Massey W, Herndon J, Healy P, Miller E, Friedman H. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. p. 112s-112s.